Opinion

L&T Publisher Earl Watt

For the second time in a matter of weeks, Donald Trump was in the sites of a would-be assassin.

This time, the shooter didn’t get off a round, but Trump’s life was again only seconds away from being taken.

And yet, no one has taken a shot at Joe Biden, or Kamala Harris or even Barack Obama.

GUEST COLUMN, David Kappos, former director of U.S. Patent Office

In late June, generic drug maker Teva Pharmaceuticals launched a generic version of Victoza, a blockbuster diabetes drug, in the United States.

Victoza is one of the first GLP-1 drugs  —  the class of wildly popular diabetes and obesity treatments that includes Ozempic and Wegovy  —  to go off-patent.

Within just a couple of years, GLP-1 drugs have rewritten the rules of diabetes and obesity treatment, offering patients the kind of sustained weight loss and glycemic control that was once the stuff of infomercial fantasy.

SAINTS PERSPECTIVE, SCCC President Brad Bennett

Time flows a little differently in higher education than it does in everyday life, so I am thinking a lot about “last year” at Seward County Community College even as we tackle the first semester of “this year.” It’s an interesting exercise and — in the case of 2023-24 — deeply rewarding.

That’s because the academic year we wrapped up in July was one of the best I’ve ever experienced. At a time when many in higher ed are feeling a slow, cold panic about the future creep in, SCCC was heating up to break records in enrollment and operations. Quite simply: We had an amazing year.

MY PERSPECTIVE, Gary Damron

In our studies of the patriarchs - leaders in ancient Israel - we began looking to them as examples of faith. What we ultimately found was that their lives and stories were more about God and His faithfulness than they were about Abraham, Isaac, Jacob, David or others. Tying that thought with another idea from Revelation - serving God above all others - led to a look at Daniel.